Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study

被引：0
|
作者：
Meredith Hoog
Rosirene Paczkowski
Ahong Huang
Rachel Halpern
Erin Buysman
Sydnie Stackland
Yiran Zhang
Ruth Wangia-Dixon
机构：
[1] Eli Lilly and Company,
[2] GSK,undefined
[3] Tigermed-BDM,undefined
[4] Optum Inc.,undefined
[5] Panalgo,undefined
[6] Elevance Health,undefined
来源：
Diabetes Therapy | 2023年 / 14卷
关键词：
Aged; Diabetes mellitus; Type 2; Retrospective studies; Glycated Hemoglobin; Dulaglutide; Insulin; Glucagon-like peptide-1 receptor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1947 / 1958
页数：11
相关论文
共 50 条
  • [1] Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study
    Hoog, Meredith
    Paczkowski, Rosirene
    Huang, Ahong
    Halpern, Rachel
    Buysman, Erin
    Stackland, Sydnie
    Zhang, Yiran
    Wangia-Dixon, Ruth
    DIABETES THERAPY, 2023, 14 (11) : 1947 - 1958
  • [2] Clinical and economic outcomes among injection-naive patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study
    Mody, Reema
    Huang, Qing
    Yu, Maria
    Patel, Hiren
    Zhang, Xian
    Wang, Liya
    Grabner, Michael
    BMJ OPEN DIABETES RESEARCH & CARE, 2019, 7 (01)
  • [3] Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study
    Hoog, Meredith
    Maldonado, Juan M.
    Wangia-Dixon, Ruth
    Halpern, Rachel
    Buysman, Erin
    Gremel, Garrett W.
    Huang, Ahong
    Konig, Manige
    DIABETES THERAPY, 2024, 15 (04) : 855 - 867
  • [4] Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study
    Meredith Hoog
    Juan M. Maldonado
    Ruth Wangia-Dixon
    Rachel Halpern
    Erin Buysman
    Garrett W. Gremel
    Ahong Huang
    Manige Konig
    Diabetes Therapy, 2024, 15 : 855 - 867
  • [5] REAL-WORLD ECONOMIC OUTCOMES AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) TREATED WITH DULAGLUTIDE (DU) VS. BASAL INSULIN (BI) IN THE US: THE DISPEL™ STUDY
    Mody, R.
    Huang, Q.
    Yu, M.
    Zhang, X.
    Wang, L.
    Grabner, M.
    Patel, H.
    VALUE IN HEALTH, 2019, 22 : S149 - S150
  • [6] Real-world comparative outcomes study in US patients with type 2 diabetes initiating basal insulin analogues
    Davis, K. L.
    Meyers, J. L.
    Tangirala, M.
    Wei, W.
    DIABETOLOGIA, 2012, 55 : S384 - S384
  • [7] Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy
    Davis, Keith L.
    Tangirala, Muralikrishna
    Meyers, Juliana L.
    Wei, Wenhui
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (09) : 1083 - 1091
  • [8] Incidence of hypoglycaemia in patients with type 2 diabetes mellitus recently initiating basal insulin in a real-world US setting
    Kazemi, M.
    Ye, F.
    Dalal, M. R.
    DIABETOLOGIA, 2015, 58 : S458 - S458
  • [9] Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
    Qian Li
    Abhishek Chitnis
    Mette Hammer
    Jakob Langer
    Diabetes Therapy, 2014, 5 : 579 - 590
  • [10] Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
    Li, Qian
    Chitnis, Abhishek
    Hammer, Mette
    Langer, Jakob
    DIABETES THERAPY, 2014, 5 (02) : 579 - 590
12345